Solid Biosciences
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Solid Biosciences generated cash of -$94,180,000, which is more than the previous year. Cash used in financing activities reached the amount of $3,122,000 last year. Net change in cash is therefore -$81,369,000.
Cash Flow
| 2015 | -4.20M | -26.80M | 51.59M |
|---|---|---|---|
| 2016 | -20.12M | -4.21M | 3.42M |
| 2017 | -43.22M | 10.54M | 77.07M |
| 2018 | -70.19M | -26.76M | 131.50M |
| 2019 | -92.71M | 24.51M | 57.87M |
| 2020 | -56.59M | 6.6M | 128.69M |
| 2021 | -77.76M | -91.08M | 134.98M |
| 2022 | -97.97M | 59.15M | 74.83M |
| 2023 | -94.18M | 9.68M | 3.12M |
SLDB Cash Flow Statement (2015 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|
Cash at beginning of period | 155.38M | 121.20M | 155.07M | 76.37M | 86.69M | 52.14M | 7.67M | 28.59M | 8.01M |
Operating activities | |||||||||
Net income | -96.01M | -85.98M | -72.18M | -88.29M | -117.22M | -74.79M | -53.17M | -23.77M | -6.66M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||||
Depreciation and amortization | 2.58M | 2.40M | 2.96M | 3.92M | 2.82M | 1.56M | 448K | 56K | 0 |
Stock-based compensation expense | 7.62M | 7.53M | 13.37M | 11.62M | 14.20M | 0 | 5.33M | 1.47M | 764K |
| Deferred income tax benefit | 7.62M | 7.53M | 13.37M | 11.62M | 14.20M | 0 | 5.33M | 1.47M | 764K |
| Changes in operating assets and liabilities: | |||||||||
Accounts receivable, net | 0 | 110K | -110K | 0 | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | -11.50M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts payable | -764K | -5.24M | 1.20M | -3.43M | 3.77M | -1.61M | 1.57M | 2.21M | 585K |
Cash generated by operating activities | -94.18M | -97.97M | -77.76M | -56.59M | -92.71M | -70.19M | -43.22M | -20.12M | -4.20M |
Investing activities | |||||||||
Purchases Of Investments | -117.42M | -182.76M | -141.24M | -401K | -31.49M | -44.32M | -18.89M | -25.69M | -26.80M |
Investments In Property Plant And Equipment | -1.51M | -3.01M | -1.28M | -899K | -4.38M | -7.77M | -2.27M | -392K | 0 |
Acquisitions Net | 0 | 31.52M | 89.80M | -7.49M | -24.51M | 0 | 0 | 0 | 0 |
Cash generated by investing activities | 9.68M | 59.15M | -91.08M | 6.6M | 24.51M | -26.76M | 10.54M | -4.21M | -26.80M |
Financing activities | |||||||||
Common Stock Issued | 2.97M | 72.55M | 134.87M | 128.69M | 49.32M | 133.68M | 79.50M | 0 | 51.59M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 2.07M | 0 | 0 | 0 | -13K | 0 | 0 | 0 |
Cash used in financing activities | 3.12M | 74.83M | 134.98M | 128.69M | 57.87M | 131.50M | 77.07M | 3.42M | 51.59M |
Net Change In Cash | -81.36M | 36.01M | -33.86M | 78.70M | -10.32M | 34.54M | 44.40M | -20.91M | 20.58M |
Cash at end of period | 74.01M | 157.21M | 121.20M | 155.07M | 76.37M | 86.69M | 52.08M | 7.67M | 28.59M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |